Using the Earnings Power Value framework with a WACC of 7.8% and normalized earnings of $1.4B, Edwards Lifesciences Corporation has a fair value of $34.35 per share. The EPV range is $29.43 – $41.61 based on WACC sensitivity (6.3% – 9.3%).
| Low | Selected | High | |
|---|---|---|---|
| Normalized Earnings | 1,398 | 1,398 | 1,398 |
| (/) WACC | 9.3% | 7.8% | 6.3% |
| Enterprise Value | 15,009 | 17,891 | 22,143 |
| (-) Net debt | -2,233 | -2,233 | -2,233 |
| Equity Value | 17,242 | 20,124 | 24,376 |
| (/) Outstanding shares | 586 | 586 | 586 |
| Fair Price | $29.43 | $34.35 | $41.61 |
Earnings Power Value (EPV) estimates what a company is worth based on its current normalized earnings, assuming zero growth. It values the business as a perpetuity: Normalized Earnings / WACC. This gives a conservative floor value — the company's worth if it never grows but maintains its current profitability.
The model normalizes earnings by: (1) using sustainable gross margins (5-year average) applied to current revenue, (2) deducting maintenance-level operating expenses (average R&D + SG&A as % of revenue), (3) applying the average effective tax rate, and (4) subtracting the average excess of CapEx over D&A (net reinvestment needed to maintain current capacity).
EPV is most useful as a comparison anchor: if the market price is below EPV, the stock may be undervalued even without any growth. If market price exceeds EPV, the premium reflects growth expectations — which may or may not materialize.